Cutter & CO Brokerage Inc. Sells 184 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cutter & CO Brokerage Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% during the 4th quarter, HoldingsChannel reports. The fund owned 7,883 shares of the biopharmaceutical company’s stock after selling 184 shares during the period. Regeneron Pharmaceuticals accounts for 1.9% of Cutter & CO Brokerage Inc.’s portfolio, making the stock its 9th biggest position. Cutter & CO Brokerage Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,924,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $37,000. Finally, Sutton Wealth Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $7.16 during midday trading on Tuesday, hitting $907.32. The company had a trading volume of 336,829 shares, compared to its average volume of 491,297. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company’s 50 day simple moving average is $952.07 and its 200 day simple moving average is $892.70. The stock has a market cap of $99.59 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the business earned $10.96 EPS. The business’s revenue was up .6% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,022 shares of company stock worth $10,552,991. Company insiders own 8.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. Truist Financial reissued a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $976.41.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.